血浆外泌体miR-618作为复发性抑郁障碍新型生物标志物的鉴定与功能研究

Abstract

Background Given the substantial clinical and financial burden of Recurrent Depressive Disorder (RDD) and the critical lack of reliable biomarkers, this study investigated plasma exosomal microRNA (miRNA) as candidate biomarkers and therapeutic targets to overcome reliance on subjective diagnosis. The pathogenesis of RDD remains incompletely understood. To this end, we focused on miR-618 and conducted in vivo functional experiments to reveal its molecular mechanism in RDD. Methods Differentially expressed miRNAs (DEmiRNAs) in plasma exosomes between RDD patients and healthy controls (HCs) were identified using high-throughput sequencing and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve analysis was used to evaluate their diagnostic value for RDD. Biological functions and pathways of DEmiRNA target genes were explored through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The miR-618 delivery vector was constructed by utilizing the exosomes secreted by HEK293 T cells. The molecular functions of miR-618 were verified through in vivo experiments. Results High-throughput sequencing analysis identified 49 DEmiRNAs between the RDD patients and HCs. Subsequent validation via RT-qPCR demonstrated marked upregulation of miR-618 and miR-223–3p expression in plasma exosomes derived from RDD patients relative to HCs. ROC curve analysis indicated that miR-618 and miR-223–3p exhibited good diagnostic performance for RDD, with areas under the ROC curve (AUC) of 0.782 and 0.762, respectively. GO and KEGG pathway enrichment analyses indicated significant associations of DEmiRNAs target genes with key biological processes such as ER to Golgi ceramide transport and calcium ion export, and specific pathways including PI3K-Akt signaling pathway, MAPK signaling pathway and Wnt signaling pathway, etc. Functional validation in vivo indicated that miR-618 contributes